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Background Pharmacological activation of cannabinoid receptors elicits antitumoral 
responses in different models of cancer. However, the biological role of 
these receptors in tumor physio-pathology is still unknown.  
Methods We analyzed CB2 cannabinoid receptor protein expression in two series 
of 166 and 483 breast tumor samples operated in the University 
Hospitals of Kiel, Tübingen and Freiburg between 1997 and 2010. CB2 
mRNA expression was also analyzed in previously published DNA 
microarray datasets. The role of CB2 in oncogenesis was studied by 
generating a mouse line that expresses the HER2 rat ortholog (neu) and 
lacks CB2, and by a variety of biochemical and cell biology approaches 
in human breast cancer cells in culture and in vivo, upon modulation of 
CB2 expression by si/shRNAs and overexpression plasmids. CB2-HER2 
molecular interaction was studied by co-localization, co-
immunoprecipitation and proximity ligation assays.   
Results We show an association between elevated CB2 expression in HER2+ 
breast tumors and poor patient prognosis. We also demonstrate that 
genetic inactivation of CB2 impairs tumor generation and progression in 
MMTV-neu mice. Moreover, we show that HER2 upregulates CB2 
expression by activating the transcription factor ELK1 via the ERK 
cascade, and that an increased CB2 expression activates the HER2 pro-
oncogenic signaling machinery at the level of the tyrosine kinase c-SRC. 
Finally, HER2 and CB2 form heteromers in cancer cells.  
Conclusions Our findings reveal an unprecedented role of CB2 as a pivotal regulator 
of HER2 pro-oncogenic signaling in breast cancer, and suggest that CB2 
may be a biomarker with prognostic value in these tumors. 
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The classical and the most recent molecular classification of breast cancer recognize a 
specific entity characterized by the overexpression of the tyrosine kinase receptor 
(TKR) HER2 (1-4). Activation of TKRs turns on key signaling pathways involved in 
cell proliferation, development, differentiation, and angiogenesis, among other 
processes (5). HER2 gene amplification/protein overexpression is detected in 20-30% of 
primary breast cancers, and is a predictor of poor prognosis and deficient response to 
chemotherapy (6). 
The endocannabinoid system (ECS) is a cell-communication system that 
participates in the control of different physiological functions such as pain perception, 
motor behavior and food intake, just to mention a few (7, 8). It consists of two 
cannabinoid-specific G protein-coupled receptors (GPCRs), CB1 and CB2, their 
endogenous ligands, and the enzymes that produce and metabolize these ligands (7, 8). 
A large number of studies demonstrates that the pharmacological activation of the ECS 
by different strategies (e.g. activation of cannabinoid receptors, inhibition of 
endocannabinoid degradation) leads to antitumoral responses (7-11). In addition, it has 
been shown that the ECS is deregulated in a variety of cancers (7, 12, 13). Although 
strong evidence points to the cannabinoid receptor CB2 as a drug target for antitumoral 
therapy in several types of cancer (11, 14), there is no information on its role in tumor 
generation and progression. Here we show an unprecedented pro-oncogenic role of the 
cannabinoid receptor CB2 in HER2+ breast cancer, and unveil that this GPCR is a 
pivotal regulator of HER2 signaling. 
 
Methods 
Tissue microarrays 
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PFA-fixed and paraffin-embedded blocks of tumor tissue from cases operated in the 
University Hospitals of Kiel, Tübingen or Freiburg between 1997 and 2010 were used 
for tissue microarray (TMA) construction by punching two 1-mm spots of each 
patient’s sample. This resulted in two series of 166 and 483 tumor samples. Complete 
histopathological information was available for all the patients. In addition, for the 483-
sample series (TMA #2), date and cause of death as well as date of local and/or distant 
relapse were also available.  
 
Immunohistochemical analysis 
Tissue sections were subjected to a heat-induced antigen retrieval step prior to exposure 
to an anti-CB2 receptor or an anti-ERBB2 primary antibody (Supplmental Table 1). 
Immunodetection was performed using the Envision method with DAB as the 
chromogen. For CB2 expression, cases were scored as 0 (no staining), 1 (weak staining), 
2 (moderate staining) or 3 (high staining). ERBB2-staining was scored according to 
HercepTest manufacturer’s guidelines.  
 
Generation of MMTV-neu:CB2-/- mice and sample collection 
All procedures involving animals were performed with the approval of the Complutense 
University Animal Experimentation Committee according to the EU official 
regulations. Generation of the congenic strain MMTV-neu:CB2-/- was accomplished by 
mating MMTV-neu mice with CB2-/-  mice (see Supplementary Methods). Females were 
palpated twice weekly for mammary gland nodules. As soon as tumors appeared, they 
were routinely measured with external caliper, and volume was calculated as (4π/3) x 
(width/2)2 x (length/2). Animals were sacrificed and mammary glands, breast tumors 
and lungs were collected (see Supplementary Methods) at the following time points: 1) 
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when the first tumor in each animal appeared, 2) 40 days after the appearance of the 
first tumor, and 3) 90 days after the appearance of the first tumor.  
 
Additional methods are available in the Supplementary Methods 
 
Results 
Elevated CB2 expression in HER2+ tumors correlates with poor patient prognosis. 
In two small cohorts of human samples, we previously reported that CB2 mRNA 
expression correlates with higher histological grades and increased HER2 expression 
(15), and that the CB2 protein was present in the vast majority of HER2+ tumors (16). 
Here, we analyzed CB2 expression in a much larger series of tissue sections [649 breast 
human samples included in different tissue microarrays (TMAs)]. CB2 expression was 
scored as 0 (no staining), 1 (weak staining), 2 (moderate staining) or 3 (high staining) 
(Figure 1A). We observed that non-tumor breast tissue expressed undetectable levels of 
CB2 (Figure 1B). Conversely, CB2 was expressed by a very large fraction of human 
breast adenocarcinomas (476 out of 629, i.e. 76%). CB2 expression was highly 
associated to HER2+ tumors (Figure 1C, p=6x10-7, Pearson’s Chi-squared test), while 
no association between CB2 expression and hormone-sensitive or triple negative tumors 
was detected (Figure 1C). Thus, 97% of the HER2+ samples scored positive for CB2 
expression (Figure 1C). Moreover, 65% of them expressed elevated levels of CB2 
(scores 2 and 3) (Figure 1C). Importantly, these HER2+/high CB2 patients had 
decreased overall survival (Figure 2A, p=0.009, Logrank test), and higher probability to 
suffer local recurrence (Figure 2B, p=0.003, Logrank test) and to develop distant 
metastases (Figure 2C, p=0.009, Logrank test) than HER2+/low CB2 (scores 0 and 1) 
patients. Similar observations were made when CB2 mRNA levels were analyzed in 
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public DNA microarray datasets (17-19) (Figures 2D-F, p=0.059 in D, p=0.036 in E, 
and p=0.007 in F, Logrank test). Of interest, this correlation was not observed in HER2- 
patients (Figures 2G-I). Together, these results show a strong association between CB2 
expression and tumor aggressiveness in HER2+ breast cancer. 
 
The lack of CB2 impairs breast tumor generation and progression. We next 
analyzed whether there was a cause and effect link between elevated CB2 expression 
and increased aggressiveness in HER2+ tumors. First, we observed that CB2 expression 
in the non-cancerous mammary glands of adult wild-type (WT) female mice was 
virtually undetectable (Supplementary Figures 1A-B). Moreover, it remained very low 
and unchanged during adult mammary gland development (Supplementary Figures 1A-
B). These results suggest that CB2 may not play a major role in the physiology of the 
healthy adult mammary gland. Next, we analyzed breast tumor generation and 
progression in an animal model of HER2-driven breast cancer (the MMTV-neu mouse) 
in which CB2 expression was knocked-out (Supplementary Figures 1C-D). MMTV-
neu:CB2-/- mice showed a striking delay in tumor onset as compared with their WT 
littermates (Figure 3A). Upon early detection, tumor histological features were very 
similar in both groups (low grade adenocarcinomas with no lymphatic invasion) 
(Supplementary Figure 1E), the only apparent difference between them being their 
mitotic index (medium in WT animals and low in the CB2-/- population) (Supplementary 
Figure 1E). Forty days after their appearance, 100% of the CB2 KO-derived tumors kept 
their original histological characteristics, while 40% of those derived from WT animals 
were solid carcinomas with necrotic areas (Supplementary Figure 1E). At the final stage 
of the disease (90 days after tumor appearance), CB2-/- tumors had negligible changes in 
their histology (although 40% of them presented necrotic areas), but the WT group 
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included 40% of solid carcinomas, 40% of tumors with necrotic areas and 20% of 
tumors with evident signs of lymphatic invasion (Supplementary Figure 1E), all of them 
signs of more aggressive tumors. 
The lack of CB2 receptors also reduced the number of tumors generated per 
animal (Figure 3B) and slowed-down tumor growth (Figure 3C). The delayed tumor 
onset and the decreased tumor multiplicity and growth associated to the lack of CB2 
receptors were accompanied by reduced levels of cyclin D1 and increased levels of the 
CDK inhibitor p21 in the tumors (Figures 3D-E), both of which are hallmarks of HER2-
induced malignant transformation and progression (20-22). In addition, the levels of the 
endocannabinoid anandamide were higher in CB2-/--derived tumors than in CB2+/+ 
tumors (Supplementary Figure 1F), and the mRNA levels of the enzyme responsible for 
anandamide degradation (FAAH) were lower in CB2-deficient tumors than in CB2 WT 
lesions (Supplementary Figure 1G). Finally, CB2 deficiency produced a remarkable 
reduction in the percentage of animals with lung metastases (Figure 3F). This phenotype 
correlated with decreased tumor levels of tenascin-C, SPARC, and COX2 (Figure 3G), 
which have been proposed to mediate metastasis specifically directed to the lungs (23). 
Together, these results indicate that CB2 plays an important role in promoting HER2+ 
breast tumor generation and progression.   
 
HER2 enhances CB2 expression by activating the transcription factor ELK1 via 
ERK. Since we observed that virtually all HER2+ human tumors express CB2 (Figure 
1), we analyzed whether HER2 controls the expression of the cannabinoid receptor. 
Ectopic overexpression of HER2 in triple negative (no estrogen receptor, progesterone 
receptor and HER2 expression) MDA-MB-231 cells resulted in an increased 
transcription of CB2 (Figure 4A). The in silico analysis of the CB2 promoter sequence 
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revealed the existence of, among others, several ELK1-binding sites (24) (Figure 4B). 
ELK1 belongs to the ETS transcription factor family, which has been related to cancer 
(25), and is a well-established target of the ERK cascade (26). We observed that HER2 
overexpression activated ELK1, an effect that was accompanied by the activation of 
ERK (Figure 4C). Of interest, incubation with the MEK inhibitor U0126 prevented the 
enhancement of p-ELK1 levels (Figure 4C). Moreover, pharmacological inhibition of 
MEK (Figure 4D) and genetic knock-down of ELK1 (Figure 4E) blocked the increase in 
CB2 mRNA levels elicited by HER2 overexpression. In the same line, ELK1 knock-
down decreased CB2 mRNA levels in breast cancer cells that endogenously overexpress 
HER2, an effect that was not observed in HER2-negative cells (Figure 4F). By 
chromatin immunoprecitation assays, we confirmed that ELK1 physically interacts with 
the CB2 promoter, and that this interaction is enhanced upon HER2 overexpression and 
prevented by inhibition of the ERK cascade (Figure 4F). Moreover, ELK1 was able to 
activate the CB2 promoter. Thus, transfection of HEK293T cells with a luciferase 
reporter encoding the CB2 gene promoter (pGL3- CB2) together with a constitutively 
active ELK1-expressing plasmid resulted in an increased luciferase activity when 
compared to cells transfected with pGL3- CB2 only (Figure 4G). Point mutations in the 
CB2 promoter revealed that the putative ELK1-binding sites located at positions -71 and 
-89 are the ones responsible for ELK1-induced activation of CB2 expression (Figure 
4G). Together, these observations demonstrate that HER2 promotes CB2 upregulation 
by activating the transcription factor ELK1 via ERK activation. Supporting the 
relevance of this observation, the analysis of 1453 human breast cancer samples from 7 
different public DNA microarrays (18, 27-32) showed a strong correlation between 
ELK1 and CB2 mRNA expression (Figures 4H-I), and the immunofluorescence analysis 
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of HER2+ breast cancer biopsies revealed that CB2-positive cancer cells presented 
nuclear ELK1 immunoreactivity (Figure 4J).  
 
HER2 forms heteromers with CB2. We next aimed at determining whether the HER2-
CB2 functional crosstalk was due to a molecular interaction between the receptors. 
Immunofluorescence analysis of human HER2+ breast cancer cells revealed that the 
two receptors colocalize (Figure 5A). Moreover, immunoprecipitation of HER2 in HEK 
cells produced the co-precipitation of CB2, and vice versa (Figure 5B). The HER2-CB2 
molecular association in cancer cells was confirmed using the proximity ligation assay. 
Thus, ectopic overexpression of HER2 in MDA-MB-231 cells enhanced the levels of 
CB2 (Figure 5C), and this effect was accompanied by the appearance of fluorescent 
dots, i.e. HER2-CB2 heteromers (Figure 5D). This fluorescent signal was not evident 
either in cells that do not express HER2 (with very low levels of CB2) or in cells in 
which CB2 expression was knocked-down by means of selective shRNA (Figure 5D). 
Importantly, the presence of HER2/CB2 heterodimers was detected in human breast 
cancer cells that endogenously overexpress HER2 (Figure 5E) and in HER2-positive 
human breast cancer tissue (Figure 5F). Again, the heteromer fluorescent signal was not 
evident either when CB2 was stably silenced in cells (Figure 5E) or in tumors that do 
not overexpress HER2 (Figure 5F). These results confirm that CB2 is upregulated by 
HER2 and support that HER2 and CB2 form heteromers in cancer cells.   
  
CB2 overexpression confers pro-oncogenic advantages on HER2+ breast cancer 
cells. We next analyzed the biological consequences of the HER2-induced CB2 
upregulation. HER2 overexpression in MDA-MB-231 cells (which effectively enhanced 
CB2 levels, Figure 5C) increased cancer cell viability (Figure 6A) and stimulated 
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properties of cancer cells intimately related to tumor progression, i.e. anchorage-
independent growth (Figure 6B) and invasion (Figure 6C). These effects were prevented 
by CB2 knock-down (Figures 6A-C). In the same line, genetic silencing of CB2 
(Supplementary Figure 1H) reduced cell viability (Figure 6D), cell invasion (Figure 
6E), colony formation in soft agar (Figure 6F) and the expression of metastasis markers 
(Supplementary Figure 1I) in cells endogenously overexpressing HER2, an effect that 
was not observed in HER2-negative cells. Moreover, the growth of MDA-MB-231 
HER2-overexpressing orthotopic xenografts (Figures 6G-H) and the generation of lung 
metastases (Figures 6I-L) were significantly impaired upon stable CB2 knock-down. 
Similarly, tumors generated from HER2-amplified cells significantly reduced their 
growth when CB2 was silenced (Figure 6M). Collectively, these data show that CB2 
promotes pro-oncogenic responses in a HER2+ context. 
 
CB2 favors HER2-induced activation of c-SRC. Next, we aimed at identifying CB2 
targets responsible for its pro-tumoral activity. Upon modulation of CB2 and HER2 
expression, and by means of a phospho-kinase array, we detected significant alterations 
in some members of the SRC family of non-receptor tyrosine kinases, which has been 
extensively related to cancer (33-35). Specifically, we found that the expression of 
phosphorylated LYN, LCK, YES, FGR, HCK and FYN decreased upon CB2 knock-
down (Figures 7A-B). However, this effect was observed both in HER2+ and HER2- 
cells (Figure 7A-B), which suggests that, although these may be relevant CB2 targets in 
breast cancer, they are not HER2+ context-specific. Of interest, the phosphorylated 
form of another member of the SRC family (c-SRC), which has particular relevance in 
cancer development and progression (33), was specifically upregulated upon HER2 
overexpression and downregulated by CB2 knock-down in that high-HER2 context 
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(Figures 7B-C). Moreover, when CB2 expression was restored in MDA-MB-231-HER2 
shCB2 cells, p-c-SRC levels were increased, an effect that was not evident in the MDA-
MB-231 that do not overexpress HER2 (Figure 7D). In the same line, a decrease in p-c-
SRC upon CB2 silencing was observed in a panel of 5 breast cancer cell lines that 
endogenously overexpress HER2 (Figure 7E).  
Next, we tested whether c-SRC was responsible for CB2-driven oncogenesis. 
First, we observed that mouse NIH/3T3 embryonic fibroblasts acquire clonogenic 
properties upon overexpression of either CB2 or HER2 (Figures 8A-B). Moreover, the 
ability of these cells to form colonies in soft agar significantly increased when the two 
receptors were simultaneously overexpressed (Figures 8A-B). Disruption of c-SRC 
signaling by using a c-SRC dominant negative construct prevented the oncogenic 
phenotype induced by CB2 plus HER2 (Figures 8A-B). Of interest, while the HER2-
mediated increased clonogenicity was prevented by blocking c-SRC signaling, the CB2-
induced clonogenic response was not (Figures 8A-B), which indicates that CB2 
promotes c-SRC activation (and the subsequent clonogenic response) via HER2. We 
then performed colony formation experiments with human HER2-amplified breast 
cancer cells. Specifically, we overexpressed CB2 in 5 HER2+ cell lines and observed an 
increase in the levels of p-c-SRC (Figure 8C). As expected, this increase in activated c-
SRC was accompanied by an enhanced clonogenicity (Figure 8D). Importantly, 
pharmacological inhibition of c-SRC with Saracatinib (a SRC family kinase/Abl dual-
kinase inhibitor) in CB2-overexpressing cells kept both clonogenicity (Figure 8D) and 
p-c-SRC expression (Figure 8C) at the same level than in pcDNA3-transfected cells 
treated with the inhibitor, which again suggests that CB2-driven oncogenesis is 
mediated by activation of c-SRC. Finally, and in further support of a causal link 
between the CB2/HER2/c-SRC axis and pro-oncogenic events, we found a decreased c-
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SRC and AKT activation in tumors generated by CB2-deficient animals [which present 
a less aggressive phenotype (Figure 3)] with respect to their WT littermates (Figures 8E 
and 8F), and the analysis of human tumor biopsies revealed that HER2+ breast cancer 
cells expressing activated c-SRC also expressed CB2 (Figure 8G). 
 
Discussion 
Here we demonstrate not only that the cannabinoid receptor CB2 exerts a remarkable 
pro-oncogenic function in HER2+ breast cancer, but also that CB2 plays a pivotal role in 
HER2-mediated pro-oncogenic signaling (Figure 8H). It is widely accepted that GPCRs 
and TKRs control critical biological processes intimately related to oncogenesis, and 
that the functional crosstalk between members of these two receptor superfamilies (e.g. 
transactivation of TKRs by GPCR-mediated signaling) may have important 
consequences in the progression and resistance to TKR-targeted therapies of some types 
of cancer (36, 37), including HER2+ breast cancer (38). In some cases, the functional 
crosstalk between GPCRs and TKRs might rely on a physical interaction between 
receptors. Regarding HER2 specifically, it has been reported that this receptor can form 
a complex with the β2-adrenergic receptor in the heart and brain, which is required for 
mitogen-activated protein kinase activation induced by multiple GPCR agonists in 
cardiac myocytes (39). Here we show for the first time that a TKR (HER2) forms 
heteromers with a GPCR (CB2) in cancer cells. These findings reveal an unprecedented 
mechanism of control of HER2 activity that involves cannabinoid receptor CB2, and 
suggest that the simultaneous targeting of the two receptors (or common downstream 
effectors) may be a reasonable therapeutic strategy. Since dual-targeting approaches are 
showing positive results in preclinical and clinical contexts when the targets are 
different members of the ERBB family (mainly ERBB1 and ERBB2) or even different 
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domains of the same receptor (neutralizing antibodies + tyrosine kinase inhibitors, for 
example) (40), it is tempting to speculate that the combination of anti-HER2 compounds 
with cannabinoids targeting CB2 may have synergistic antitumoral effects. Interestingly, 
there is evidence showing that, at least at the preclinical level, the combination of 
cannabinoids with other anticancer therapies results in improved responses when 
compared with the corresponding individual treatments (11, 41-44). In any case, further 
studies should be performed to unveil the functional relevance of the HER2-CB2 
heteromers.  
Our findings also show that the non-receptor tyrosine kinase c-SRC plays a 
pivotal role in CB2-induced HER2 pro-oncogenic signaling (Figure 7). c-SRC promotes 
cell proliferation, survival, migration and angiogenesis (33), and its deregulation is 
associated with oncogenesis (34, 35) and poor patient prognosis (45). Together, these 
features made c-SRC an excellent target for the clinical development of specific 
inhibitors (34, 35, 45, 46). In HER2+ breast cancer in particular, c-SRC activation has 
been implicated in the generation of brain metastases (47), a condition that has no 
curative treatment, and in the development of trastuzumab resistance (48). Interestingly, 
treatment of brain metastasis-bearing mice with a combination of Lapatinib (which 
targets ERBB1 and ERBB2) and a c-SRC inhibitor slowed-down the growth of the 
metastases (47), and treatment of trastuzumab-resistant cells/tumors with a c-SRC 
inhibitor restored trastuzumab resistance (48). These data suggest that blocking c-SRC 
may be an effective manner to treat two important remaining clinical challenges in 
HER2+ breast cancer: the treatment of highly metastatic tumors (especially those 
colonizing the central nervous system) and trastuzumab resistance (both innate and 
acquired). Additional experiments should be performed to analyze the involvement of 
CB2 in c-SRC-mediated trastuzumab resistance and generation of brain metastasis. 
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Our results clearly reveal a pro-oncogenic role of CB2 in HER2+ breast cancer. 
However, it has been widely described that pharmacological activation of this particular 
receptor exerts antitumoral effects in different models of breast (15, 16, 49, 50) and 
many other types of cancer (11). Further experiments should be performed to get a 
deeper insight into the molecular details of this bimodal effect of CB2 receptor 
functionality. For example, it would be interesting to know whether different 
cannabinoid stimuli (i.e. an endogenous tone vs an exogenous pharmacological 
activation) produce a different activation of CB2/HER2-mediated signaling in terms of 
intensity and/or specific pathways. 
Finally, we have observed a strong association between higher CB2 protein 
expression in HER2+ breast tumors and lower patient overall, relapse-free and 
metastasis-free survival. It has been previously shown that the levels of CB2 are 
elevated in breast (15, 16, 50) and many other types of cancer compared to healthy 
matching tissue (11), and in the more aggressive (high grade) breast (15, 16) and brain 
(51-53) tumors compared to the respective less aggressive (low grade) tumors. 
Recently, an association between CB2 expression and overall and disease-free survival 
of patients with squamous cell carcinoma of the head and neck has also been reported 
(54). All these observations may serve to exploit CB2 as a new prognostic marker in 
oncology (at least in certain types of tumors).   
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Figure legends 
Figure 1. CB2 expression associates with HER2+ breast tumors. A) Representative 
images showing CB2 expression scoring according to intensity staining in tissue 
microarray (TMA) samples: scores 0, 1, 2 and 3 correspond to no, low, moderate and 
high staining, respectively. B) Representative CB2 immunohistochemical staining in a 
human non-tumor breast tissue sample included in the analyzed TMAs. Inset, CB2 
staining (brown) in a macrophage is shown as a CB2 staining-positive control. C) 
Association between CB2 expression (as determined by staining scoring) and the 
molecular features of breast tumor samples included in the TMAs. The Pearson’s chi-
squared test was used for statistical analysis.  
 
Figure 2. Elevated CB2 expression in HER2+ breast tumors correlates with poor patient 
prognosis. Kaplan-Meier curves for overall survival (A, D-G), survival with no 
recurrence in the breast (B and H) and metastasis-free survival (C and I). Data plotted 
in panels A-C correspond to the 65 HER2+ samples included in TMA # 2 (see 
Methods). Data plotted in panels G-I correspond to the 224 HER2- samples included in 
TMA # 2. Data plotted in panels D and E were obtained from the microarray data sets 
published in ArrayExpress database (accession number E-TABM-158) (D) and GEO 
database (accession number GSE3143) (E). Data plotted in F were obtained from (19) 
through the Kaplan-Meier Plotter (www.kmplot.com). Survival curves were statistically 
compared by the Logrank test. 
 
Figure 3. The lack of CB2 impairs breast tumor generation and progression. A) Kaplan-
Meier curves for tumor onset in MMTV-neu:CB2 WT and MMTV-neu:CB2 KO mice. 
Results were analyzed by the Pearson’s chi-squared test. B) Number of tumors 
24 
 
generated per animal 90 days after first tumor arousal. C) Tumor volume 70 days after 
tumor appearance. D) Western blot analysis of Cyclin D1 and p21 in tumors generated 
by the indicated animals. Three representative samples per experimental group are 
shown. E) Densitometric analysis of the levels of the indicated proteins (determined by 
Western blot; n=7 for MMTV-neu:CB2 WT tumors and n=6 for MMTV-neu:CB2 KO 
tumors). Results are expressed in arbitrary units. F) Percentage of animals with lung 
metastases 90 days after tumor arousal. Lung tumor masses were classified as 
macrometastases when they were visible to the naked eye at dissection, and as 
micrometastases when they were only detectable by H&E staining. G) mRNA levels (as 
determined by real-time quantitative PCR) of Tenascin C, SPARC and COX2 in tumors 
generated by the indicated mice. Results are expressed in arbitrary units. Except in A, 
data were analyzed by ANOVA with a post-hoc analysis by the Student–Newman–
Keuls’ test. *, p0,05; **, p 0,01 vs MMTV-neu:CB2 WT mice.    
 
Figure 4. HER2 enhances CB2 expression by activating the transcription factor ELK1 
via ERK. A) ERBB2/HER2 protein expression (upper panel) and CB2 mRNA 
expression (lower panel) in MDA-MB-231-HER2 (231-HER2) and MDA-MB-231 cells 
(231). B) Schematic representation of the CB2 gene promoter sequence. The positions 
and sequences of the putative ELK1-binding sites are indicated. C) Western blot 
analysis of the indicated proteins, in the presence or in the absence of the MEK inhibitor 
U0126 (5 µM). D-E) CB2 mRNA expression (in arbitrary units), in the 
presence/absence of U0126 (D), or after transfection with ELK1 siRNAs (siELK1) or 
with a non-targeted siRNA (siC) (E). F) Effect of ELK1 knock-down on CB2 mRNA 
expression (top panel) in different human breast cancer cells endogenously 
overexpressing (black bars) or not (gray bars) HER2. Results are expressed in arbitrary 
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units vs the corresponding cells transfected with a control siRNA (siC), set at 1 in all 
cases (white bar). The bottom panel shows the ELK1 mRNA levels found in the cells 
after ELK1 silencing. G) ChIP assay in cells treated with or without U0126. 
Immunoprecipitation was performed with an anti-ELK1 Ab (or a non-specific rabbit 
IgG as control). G) CB2 gene promoter activity as determined by a luciferase reporter. 
Drawings (left) represent the CB2 promoter construct transfected in each case. A 
constitutively active ELK1 containing plasmid was always co-transfected with the CB2 
promoter. Line 1, CB2 promoter empty vector. H and I) Correlation of CB2 and ELK1 
expression (analyzed by the Pearson’s chi-squared test) in human breast cancer samples 
from 7 public DNA microarrays [(18, 22, 26, 28, 29, 31) in H and (28) in I]. J) 
Immunofluorescence analysis of CB2 (green) and phospho-ELK1 (red) in a HER2-
positive (upper panels) and a HER2-negative (lower panels) human breast cancer 
sample. Cell nuclei are stained in blue. Scale bar, 100 µm. Except in I and J, data were 
analyzed by ANOVA with a post-hoc analysis by the Student–Newman–Keuls’ test. **, 
p0,01 vs vehicle-treated (D) or siC-transfected (E) 231 cells; #, p0,05 vs vehicle-
treated (D) or siC-transfected (E) 231-HER2 cells; **, p0,01 vs WT (H). 
 
Figure 5. HER2 forms heteromers with CB2. A) Immunofluorescence analysis of CB2 
(green) and HER2 (red) protein expression in a HER2-positive (upper panels) and a 
HER2-negative (lower panels) human breast tumor sample. Cell nuclei are stained in 
blue. Scale bar, 100 µm. B) Analysis of the HER2-CB2 molecular interaction by 
immunoprecipitation assay in HEK cells transfected with an ERBB2 overexpression 
plasmid, a HA-tagged CB2 plasmid, both of them simultaneously or the corresponding 
empty vector (pcDNA3). C) CB2 mRNA expression, as determined by real-time 
quantitative PCR and expressed in arbitrary units, in MDA-MB-231 cells (231) or 231 
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cells stably overexpressing HER2 (231-HER2), upon stable knock-down of CB2 with a 
selective shRNA (shCB2) pool or after infection with lentiviral particles containing a 
scrambled shRNA (shC). D-F) Proximity ligation assays in 231 shC cells and in 231-
HER2 cells infected with either shC or shCB2 particles (D), in BT474 shC and BT474 
shCB2 cells (E), and in a HER2-negative and a HER2-positive human breast cancer 
sample (F). Cell nuclei are stained in blue and the red fluorescent signal correspond to 
CB2/HER2 heteromers. Scale bars, 20 µm.  
 
Figure 6. CB2 overexpression confers pro-oncogenic advantages on HER2+ breast 
cancer cells. A-F) Cell viability as determined by the MTT test (A and D), invasion in 
matrigel-coated  Boyden chambers (B and E), and number of colonies generated in soft 
agar (C and F) of MDA-MB-231 (231) and MDA-MB-231-HER2 cells (231-HER2) 
stably expressing a shRNA selectively targeting CB2 (shCB2) or a scrambled shRNA 
(shC) (A-B) or of the indicated HER2-positive or HER2-negative cell lines (D-F). G) 
Schematic representation of the generation of the orthotopic xenografts analyzed in H 
and M. H and M) Evolution of tumor volume in mice injected with either 231 or 231-
HER2 cells stably expressing shCB2 or shC (H), or with the indicated HER2-ampified 
cells stably expressing the same shRNAs (M). I) Cartoon representing the generation of 
the lung metastases analyzed in K and L, by injection of lung-seeking MDA-MB-231-
HER2 cells (231-HER2-LM) stably expressing shCB2, or a shC, into the mouse lateral 
tail vein. J) CB2 mRNA expression in shC- and shCB2-231-HER2-LM cells. K) 
Evaluation of the number of lung metastases generated per animal. L) Representative 
lung bioluminescence images (left panels) and quantification of the luminescence signal 
(right panel) in the two experimental groups. Data were analyzed by ANOVA with a 
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post-hoc analysis by the Student–Newman–Keuls’ test.*, p0,05 and **, p0,01  vs the 
corresponding shC cell line; #, p0,01 vs shC-231-HER2 cells. 
 
Figure 7. Involvement of c-SRC in CB2-induced HER2-mediated pro-oncogenic 
signaling. A) Phospho-kinase protein array analysis in MDA-MB-231 (231) and MDA-
MB-231-HER2 cells (231-HER2) after stable knockdown of CB2 by means of selective 
shRNA. Squared dots correspond to the following SRC kinase family members: 1, 
LYN; 2, LCK; 3, YES; 4, FGR; 5, HCK; 6, c-SRC and 7, FYN. Note that in this 
phosphoarray kit, each condition consist of two membranes. B) Densitometric analysis 
of the squared dots shown in A. C-E) Western analysis of the indicated proteins in 
MDA-MB-231 (231) and MDA-MB-231-HER2 (231-HER2) cells stably expressing a 
shRNA selectively targeting CB2 (shCB2) or a scrambled shRNA (shC) (C), or in 231 
shCB2 or 231-HER2 shCB2 cells stably expressing a HA tagged-CB2 plasmid (HA-CB2) 
or the corresponding empty vector (pcDNA3) (D), or in the indicated HER2-amplified 
cells stably expressing shCB2 or shC (E). Numbers in E correspond to the densitometric 
analysis of the respective bands.  
 
Figure 8. Involvement of c-SRC in CB2-induced HER2-mediated pro-oncogenic 
signaling. A-D) Anchorage-independent growth (A and D) and expression of ERBB2, 
HA-CB2 and the indicated proteins (B and C) (as determined by Western blot), in 
NIH/3T3 fibroblasts (A and B) and in a panel of 5 HER2+ human breast cancer cell 
lines (C and D) transiently transfected with the indicated constructs and/or incubated 
with 1µM Saracatinib. In B and C (AU565 cells), lanes were run on the same gel but 
were noncontiguous. E and F) Western blot (left panels) and densitometric analysis 
(right panels) of phospho-c-SRC (E) and phosphor-AKT (F) in breast tumors generated 
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by MMTV-neu:CB2 WT and MMTV-neu:CB2 KO mice. G) Immunofluorescence 
analysis of CB2 (green) and phospho-c-SRC (red) in a human HER2+ breast tumor 
sample. Cell nuclei are stained in blue. Scale bar, 100 µm. H) Proposed role of CB2 in 
HER2-driven pro-oncogenic signaling: HER2 enhances CB2 expression by activating 
the transcription factor ELK1 via ERK. Increased CB2 expression promotes HER2 pro-
oncogenic signaling by activating the tyrosine kinase c-SRC. Data were analyzed by 
ANOVA with a post-hoc analysis by the Student–Newman–Keuls’ test. *, p0,05 and 
**, p0,01 vs pcDNA3; #, p0,05 vs CB2 o HER2; &&, p0,01 vs HER2; $, p0,05 vs 
HER2-CB2 (A and D). *, p0,05 vs MMTV-neu:CB2 WT mice (E and F). 
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Supplementary Figure 1. (A-G) Mice tumour characterization. A) Analysis of CB1 and CB2 
mRNA expression by microarray analysis in non-cancerous mammary glands of adult wild-
type C57Bl/6 mice at the indicated time points of the pregnancy cycle. V, 8 week-old virgin 
mice. Time is expressed in days. B) Immunofluorescence staining of CB2 (red) in 
representative tissue sections of the different stages of the adult mammary gland development. 
E-Cadherin (green) staining was performed for epithelial cell visualization and cell nuclei 
were stained in blue. A mammary lymph node is shown as a positive control of CB2 
expression. C-D) CB2 and NEU mRNA [as determined by RT-PCR (C)] and protein 
expression [as determined by immunohistochemical analysis (D)] in representative tumour 
samples obtained from MMTV-neu:CB2 WT and MMTV-neu:CB2 KO mice. E) H&E staining 
of tumour sections obtained at tumour arousal (T0) or forty (T40) or ninety (T90) days after 
tumour appearance. Scale bars, 200 µm except in T0 lower pannels (100 µM). Arrows point to 
cells undergoing mitosis. * in WT T40 shows a necrotic area, and in WT T90 a lymphatic 
invasion. F-G), Anandamide levels [AEA, as determined by LC-MS (F)] and FAAH mRNA 
levels [as determined by real-time quantitative PCR (G)] in tumour samples from the 
indicated animals at the indicated time points. (H and I) mRNA expression of the indicated 
proteins in HER2- (grey bars) and HER2+ (black bars) breast cancer cell lines upon stable 
transfection with a shRNA selectively targeting CB2 (shCB2). Results are expressed in 
arbitrary units vs the corresponding shC transfected cells, set at 1 (white bars). ND, non 
detected. *, p0,05 and **, p0,01 vs MMTV-neu:CB2 WT T0; #, p0,05 and ##, p0,01 vs 
MMTV-neu:CB2 KO T0; &, p0,05 and &&, p0,01 vs the corresponding WT.   
Supplementary Methods 
Generation of MMTV-neu:CB2
-/-
 mice and sample collection 
Generation of the congenic strain MMTV-neu:CB2
-/- 
was accomplished by mating 
MMTV-neu mice (The Jackson Laboratory, Bar Harbor, Maine) with CB2
-/-  
mice (NIH, 
Bethesda, Maryland). To transfer the CB2 line (with a C57BL/6J background) to the 
genetic background of the tumor-prone animals (FVB/NJ), the descendants were 
backcrossed with MMTV-neu mice for 6 generations, using a marker-assisted selection 
protocol (MASP) (1). In short, the offspring of each generation was genotyped for CB2. 
Heterozygous animals were genotyped for a set of 377 single nucleotide polymorphisms 
(SNPs) using the Mouse Low Density Linkage Panel from Illumina. Selected breeders 
for the next generation were those with the highest percentage of FVB/NJ-linked SNPs. 
After 6 backcrosses, animals presented more than 99% FVB/NJ background. CB2
+/-
 
mice from this generation were then crossed between them to generate MMTV-
neu:CB2
-/- 
and their corresponding control littermates (MMTV-neu:CB2
+/+
). A total of 
53 MMTV-neu:CB2
+/+
 (10 for each time point 1 and 2, and 33 for time point 3) and 46 
MMTV-neu:CB2
-/-
 (10 for each time point 1 and 2, and 26 for time point 3) female mice 
were analyzed. 
After animal sacrifice, mammary glands and lungs were fixed in 4% 
paraformaldehide (PFA). Before PFA fixation, lungs were visually analyzed for 
macroscopic metastases. Microscopic metastases were determined by H&E staining of 
PFA-fixed paraffin-embedded sections. Tumors were divided in four portions for 1) 
preparation of tissue sections for immunofluorescent staining [frozen in Tissue-Tek 
(Sakura Finetek Europe, Zoeterwoude, The Netherlands)], 2) preparation of tissue 
sections for H&E staining (fixed in buffered 4% PFA), 3) protein extraction (snap 
frozen), and 4) RNA isolation (snap frozen), and were stored at -80ºC until analysis 
(except PFA-fixed tumor fractions, that were kept at room temperature). 
 
Generation of xenografts 
For the generation of orthotopic tumors, 2x106 viable cells were injected into the fourth 
right mammary fat pad of anesthesized 6 week-old SCID female mice (Harlan 
Interfauna Iberica, Barcelona, Spain). Tumor volume was routinely measured, and 50 
days after tumor detection, animals were sacrificed and tumors were collected and 
processed as described above. 
 
Generation of lung metastases 
231/LM2-4 luciferase-expressing cells [a lung-seeking metastatic variant of the MDA-
MB-231-HER2 cell line (2)] (5x105) were injected into the lateral tail vein of 6 week-
old SCID female mice. Forty five days after cell injection, animals were analyzed by 
bioluminescence in an IVIS 2000 system (Xenogen Corp, Alameda, CA). Imaging data 
were processed with Living Image software (Xenogen Corp). Mice were then sacrificed 
and lungs were collected for metastatic nodule quantification by H&E staining.  
  
Western blot analysis 
Lysates from tumors and cell lines were subjected to SDS–PAGE, and proteins 
transferred onto PVDF membranes. Blots were incubated with the antibodies indicated 
in Supplementary Table 1. Luminograms were obtained with the Amersham Enhanced 
Chemiluminescence Detection Kit (GE Healthcare, Uppsala, Sweden) and densitometric 
analysis was performed with Quantity One software (Bio-Rad, Madrid, Spain). 
 
RT– and real-time quantitative (Q)–PCR, and analysis of published microarray 
datasets 
RNA was isolated with Trizol Reagent (Invitrogen, Barcelona, Spain) with the Real Star 
Kit (Durviz, Valencia, Spain), and cDNA was obtained with Transcriptor Reverse 
Transcriptase (Roche Applied Science, Barcelona, Spain). The primers used for RT– 
and Q–PCR are in Supplementary Table 2. For Q–PCR, probes were from the Universal 
Probe Library (Roche Applied Science) and multispecies 18S RNA was used as 
reference. For RT–PCR, GAPDH was used as reference. CB1 and CB2 mRNA 
expression in mouse mammary tissue was analyzed in the dataset published in (3). 
Human CB2 and ELK1 mRNA expression were obtained from microarray datasets 
published in (4), (5), (6), (7), (8), (9), (10) and (11). The combined raw gene expression 
of the first 6 micro-array datasets was obtained from the “R2: microarray analysis and 
visualization platform” (http://r2.amc.nl), specifically from the Tumor Breast 
compendium -Halfwerk-947-complex-u133a. 
 
Immunofluorescence analysis 
Tissue-Tek or paraffin-embedded sections were fixed in 10% PFA and subjected to 
heat-induced antigen retrieval in citrate buffer before exposure to the primary antibodies 
indicated in Supplementary Table 1. Cell nuclei were stained with DAPI (Invitrogen). 
Fluorescence confocal images were acquired by using Leica TCS-SP2 software (Leica, 
Wetzlar, Germany). Immunofluorescence analysis of CB2 receptor was performed in 
mammary gland sections from wild type C57Bl/6 mice at different points of the 
mammary gland development as previously described (12).  
 
Cell cultures, siRNA, shRNA, dominant negative and overexpression experiments 
The following cell lines were from ATCC-LGC (Barcelona, Spain): MDA-MB-231 and 
MDA-MB-468 (ER-/PR- and HER2-), MCF-7 and T47D (ER+ and HER2-),  and 
BT474, MDA-MB-361, SKBr3, HCC1954 and AU565 (HER2+) human breast 
adenocarcinoma cells, HEK cells and NIH/3T3 mouse embryonic fibroblasts. MDA-
MB-231-HER2 cells (a MDA-MB-231 variant that stably overexpresses HER2 (13)) 
and 231/LM2-4 cells were kindly donated by Dr. Kerbel (University of Toronto, 
Canada). All cell lines (except BT474, which was cultured in RPMI) were maintained in 
DMEM supplemented with 10% FBS. To stably knockdown CB2, lentiviral particles 
containing 3 target-specific shRNA constructs were used. A scrambled shRNA 
construct was used as control (Santa Cruz Biotechnology, Santa Cruz, CA). Stably 
infected cells were selected with puromycin. For transient knock-down, a pool of 
double-stranded siRNA duplexes for human ELK1 (Thermo Scientific, Spain) were 
used. Sequences were: 5’-GCAAGGCAAUGGCCACAUC-3’, 5’-
CGGAAGAGCUUAAUGUGGA-3’, 5’-GCCAGAAGUUCGUCUACAA-3’, and 5’-
GCAGCAGCCGGAACGAGUA-3’. The nontargeted control siRNA was from Applied 
Biosystems-Ambion (Austin, TX) and the sequence was 5’-
UUCUCCGAACGUGUCACGU-3’. DharmaFECT 3 (Thermo Scientific) was used as 
transfection reagent. For overexpression experiments, pLNCX-cSRC K296R/Y528F 
[dominant negative (Millipore Iberica, Madrid, Spain)], pcDNA3-HA-hCB2 (University 
of Missouri-Rolla cDNA Resource Center, Rolla, MO), pcDNA3-hERBB2 (kindly 
donated by Dr. Pandiella, Cancer Research Center, Salamanca, Spain), or the 
corresponding empty vector (pcDNA3, Invitrogen) were used. Lipofectamine 2000 
(Invitrogen) was used as transfection reagent. Cell viability was determined by the MTT 
test (Sigma-Aldrich, Spain) according to manufacturer’s instructions.  
 
Chromatin immunoprecipitation (ChIP) assays 
Cells were processed as recommended by the manufacturer (EZ-ChIP, Millipore) and 
immunoprecipitation was performed with an anti-ELK1 antibody (Supplementary Table 
1) or a non-specific rabbit IgG as control. ELK1-bound DNA was determined by RT-
PCR analysis. Primers for the amplification of ELK1-binding DNA sequences in the 
CB2 promoter region (14) were: Forward: 5´-TGGTAACAGGCACGGAAGGC-3´; 
Reverse: 5´-TGAGTGCCACCCCAAGCCAG-3´. 
 
Co-immunoprecipitation experiments 
HEK-293T cells were transiently transfected with expression vectors pcDNA3-HA-
hCB2, pcDNA3-hERBB2 and pcDNA3 empty vector, using Lipofectamine Plus as 
transfection agent. Cells were lysed in IP buffer and proteins were immunoprecipitated 
using anti-HA or anti-ERBB2 antibodies (Supplementary Table 1) coupled to protein G-
Sepharose. 
 
In situ proximity ligation assays 
Heteromers were detected using the Duolink II in situ PLA detection Kit (OLink 
Bioscience, Uppsala, Sweden). Cells were incubated with a mixture of equal amounts of 
anti-HER2 antibody (Supplementary Table 1) directly coupled to a DNA plus chain, 
and anti-CB2 antibody (Supplementary Table 1) directly coupled to a DNA minus 
chain, obtained following the instructions of the supplier. Amplification was done with 
the Duolink II Detection Reagents Red Kit. The samples were observed in a Leica SP2 
confocal microscope. Images were processed with Image J software. 
 
Anchorage-independent growth 
Cells were suspended in DMEM supplemented with 10% FBS and 0.35% agar, layered 
on top of a solid 0.5% agar base in 6-well plates, and incubated at 37°C and 5% CO2 
for 45 days. The resulting colonies were morphologically assessed and quantified after 
staining with crystal violet. 
 
Cell invasion 
Cells were suspended in DMEM and loaded onto the upper compartment of BD 
BioCoat Matrigel Invasion Chambers (BD Biosciences, Bedford, MA). FBS (10%) was 
used as chemoattractant in the lower compartment. Cell invasion was quantified by 
staining migrated cell nuclei with DAPI. 
 
Quantification of anandamide levels 
Tissue samples were weighted and homogenized in chloroform:methanol:Tris HCl 50 
mM (pH =7.5) [2:1:1 (v:v:v)]. d8-AEA (Cayman Chemical) was added as internal 
standard. The organic and aqueous layers were separated by centrifugation and the 
organic layer transferred to a clean vial and dried under a stream of argon. The resulting 
fraction was reconstituted in acetonitrile and analyzed by high-pressure liquid 
chromatography coupled to mass spectrometry (LC-MS). LC-MS analysis was 
performed using an Agilent 1200LC-MSD VL instrument. LC separation was achieved 
with a Zorbax Eclipse Plus C18 column (5 m, 4.6 mm x 50 mm) together with a guard 
column (5 m, 4.6 mm x 12.5 mm). The gradient elution mobile phases consisted of A 
(95:5 water:acetonitrile) and B (95:5 acetonitrile:water), with 0.1% formic acid as the 
solvent modifier. The gradient (flow rate of 0.5 mL/min) started at 0% B (for 5 min), 
increased linearly to 100% B over the course of 45 min, and decreased to 0% B for 10 
minutes before equilibrating for 5 min with an isocratic gradient of 0% B. MS analysis 
was performed with an electrospray ionization source. LC-MS measurements were 
made by selected ion monitoring in positive mode. Fractions were quantified by 
measuring the area under the peak and normalized using d8-AEA as internal standard 
and absolute AEA levels were estimated by comparison with the respective deuterated 
standard. 
 Phosphoarray analysis 
A phospho-kinase protein array (R&D Systems, Abingdon, UK) was used for the 
simultaneous analysis of 43 different phosphorylation sites by a Western blot-based 
technique. Cell lysates were incubated with the nitrocellulose membranes provided by 
the phospho-array. The array was washed to remove unbound proteins and incubated 
with biotinylated detection antibodies. Membranes were then incubated with 
streptavidin-HRP and chemoluminiscence reagents. The densitometric analysis was 
performed with Quantity One software.   
 
Gene promoter activity assays 
A DNA fragment from the immediate upstream region of the CB2 receptor gene CNR2 
(-614 to +243) was amplified by PCR using human genomic DNA as template and the 
following primers: Forward: 5´-CCCGGGTATACTCCCAAGCAGAAAAG-3´; 
Reverse: 5´-CTCGAGATACAGGTGTTGGGGAATGA-3´. The 0.85-kb PCR product 
was cloned using the StrataClone PCR Cloning Kit (Agilent Technologies España, 
Madrid, Spain) and sequenced with an ABI 3730xl sequencer using T7 reverse and T3 
forward primers. Then, it was subcloned into the pGL3 luciferase reporting vector 
(Promega, Madison, WI) using XmaI (Thermo Scientific). To generate the pGL3-CB2 
promoter plasmids containing point mutations in the predicted ELK1-binding sites, 
QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) was used with 
the primers indicated in Supplementary Table 2. HEK293T cells were transiently 
transfected with the following plasmids: pGL3-hCB2 or pGL3-hCB2 mutated plasmids 
in combination with pCMV5-ELK1-HA plasmid (kindly provided by Dr. Sharrocks, 
University of Manchester, UK); a constitutively active ELK1 construct (Ser383Asp; 
Ser389Asp; generated with a QuikChange Site-Directed Mutagenesis Kit; Stratagene); 
or an empty vector. Transcriptional promoter-driven luciferase activity was analyzed 
with the Dual-Luciferase Reporter Promega Assay System (Promega) in a Lumat 
LB9507 luminometer. Renilla-derived luciferase activity was used as internal 
transfection control. 
 
Statistical analysis 
The Pearson’s chi-squared test was used for statistical analysis of the human samples 
included in the TMAs. Kaplan-Meier survival curves were statistically compared by the 
Logrank test. ANOVA with a post-hoc analysis by the Student–Newman–Keuls’ test 
was routinely used for the rest of the analyses. Unless otherwise stated, data are 
expressed as mean±s.e.m. All statistical tests were two-sided, unless otherwise 
specified. 
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